Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865904 | 1.00 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL5179147 | 1.00 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1206182 | 0.89 | ADRB2 (0.47) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL18993729 | 0.89 | ADRB2 (0.49) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2795110 | 0.89 | ADRB2 (0.47) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2568651 | 0.88 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL30490482 | 0.88 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL18993739 | 0.88 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL18946383 | 0.88 | ADRB2 (0.48) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL99134 | 0.88 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | LOHSE OLIVIER (FR) | 2012-08-30 | — | — | US | claimed |
| EP-1791820-B1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | claimed |
| US-20090054653-A1 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | LOHSE OLIVIER | 2009-02-26 | — | — | US | claimed |
| EP-1791820-A2 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | Novartis AG (CH) | 2007-06-06 | — | — | EP | claimed |
| WO-2005123684-A2 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | claimed |
| EP-3138837-B1 | INDACATEROL FREE BASE IN SOLID FORM | CRYSTAL PHARMA SAU (ES) | 2021-11-24 | — | — | EP | disclosed |
| EP-3848354-A1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | Crystal Pharma, S.A.U. (ES) | 2021-07-14 | — | — | EP | disclosed |
| EP-3848354-A1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | Crystal Pharma, S.A.U. (ES) | 2021-07-14 | — | — | EP | disclosed |
| US-10040765-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | CRYSTAL PHARMA S.A.U. (ES) | 2018-08-07 | — | — | US | disclosed |
| US-10040765-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | CRYSTAL PHARMA S.A.U. (ES) | 2018-08-07 | — | — | US | disclosed |
| US-10040765-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | CRYSTAL PHARMA S.A.U. (ES) | 2018-08-07 | — | — | US | disclosed |
| EP-2897937-B1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | CRYSTAL PHARMA SAU (ES) | 2017-12-06 | — | — | EP | disclosed |
| EP-1613599-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005123684-A2 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| EP-1599450-A1 | PROCESS FOR PREPARING 5-\"(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMIN O)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004087668-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004076422-A1 | PROCESS FOR PREPARING 5-‘(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMINO)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| US-5750701-A | Heterocyclic ethanolamine derivatives with β-adrenoreceptor agonistic activity | SMITHKLINE BEECHAM PLC (GB) | 1998-05-12 | — | — | US | disclosed |
| EP-0750617-A1 | NOVEL HETEROCYCLIC ETHANOLAMINE DERIVATIVES WITH BETA-ADRENORECEPTOR AGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025104-A1 | NOVEL HETEROCYCLIC ETHANOLAMINE DERIVATIVES WITH BETA-ADRENORECEPTOR AGONISTIC ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054653-A1 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | HAX1, OPRK1, OPRD1 | ADRB2 21/4885ADRB1 19/4885DRD2 259/4885 |
| US-10040765-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | SQLE, HSD11B1, CYP51A1 | ADRB2 130/4885ADRB1 94/4885DRD2 3254/4885 |
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | OPRM1, OPRD1, HAX1 | ADRB2 23/4885ADRB1 31/4885DRD2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.